The death of Australian actor and martial artist Richard Norton has raised serious questions about the growing use of experimental peptide treatments and how they are regulated. What began as an attempt to address physical discomfort, muscle loss and recovery ultimately became the subject of a major coronial investigation, exposing concerns about prescribing decisions, medical monitoring and the safety of unapproved therapeutic products.
More than a year after Norton’s death, a Victorian Coroners Court finding has brought the circumstances into sharper focus. The investigation has also placed two particular peptides, CJC1295 and Ipamorelin, under renewed regulatory scrutiny, with Australia’s medicines regulator now facing recommendations to reconsider the restrictions surrounding their use.
Richard Norton’s Death: What Happened Before the Fatal Peptide Injection?
Australian actor, martial artist and stuntman Richard Norton died on March 30, 2025, at Melbourne’s Alfred Hospital, aged 75. According to findings handed down by Victorian Coroner David Ryan on October 28, 2026, an injection of CJC1295 and Ipamorelin triggered an anaphylactic reaction that led to cardiac arrest.
Norton had established a career across acting, stunt work, martial arts instruction and the film and television industry. He worked on productions involving major Hollywood performers and became known for his martial arts expertise and action work, including training performers for film productions.
However, his medical history was also an important part of the investigation. The coronial finding recorded that Norton had asthma, osteoarthritis and previous bilateral shoulder reconstructions. Asthma and hypertrophic cardiomyopathy were subsequently identified as contributing factors in the fatal outcome.
Following Another Celebrity Inquest
Readers interested in how coroners investigate unexpected deaths may also want to see our coverage of another high-profile inquest. For related coverage, see our Lauren Bennett inquest report.
Why Richard Norton Sought CJC1295 and Ipamorelin Treatment
The events leading to Norton’s death began several weeks before the fatal incident.
On March 11, 2025, Norton consulted medical practitioner Dr. Jerzy Muchnicki after expressing an interest in peptide therapy. He explained that another practitioner had previously prescribed peptides to him.
The treatment was associated with several concerns, including fatigue, reduced physical recovery, shoulder pain and loss of lean muscle mass.
According to the coroner’s finding, Muchnicki reviewed Norton’s medical history and discussed the experimental nature of peptide therapy. They also considered potential risks and the absence of other alternative treatments approved by the Therapeutic Goods Administration (TGA) for the particular purpose Norton was seeking treatment for.
Norton subsequently signed an informed-consent form covering the proposed treatment, its potential benefits and its risks, including the possibility of anaphylaxis.
Muchnicki also arranged blood tests to establish baseline health information and identify possible contraindications or underlying conditions that could influence the treatment decision.
The peptides were prescribed on March 19
Following the assessment, Norton was prescribed injectable CJC1295 and Ipamorelin on March 19, 2025.
The products were compounded for him by a licensed compounding pharmacy in Queensland. Neither substance was an approved therapeutic product listed on Australia’s Australian Register of Therapeutic Goods (ARTG).
Their use therefore fell within Australia’s access arrangements for certain unapproved therapeutic goods rather than the ordinary approval pathway for registered medicines.
Initially, Norton appeared to respond positively. On March 25, he told Muchnicki that he was feeling good and that the treatment was improving his symptoms.
Richard Norton Was Taking Double the Prescribed Peptide Dose
A particularly important development emerged just two days before Norton’s death.
On March 28, 2025, Norton contacted a nurse at Muchnicki’s clinic after explaining that he had dropped and broken a vial containing CJC1295 and Ipamorelin and needed a replacement.
During the conversation, he reported better sleep, reduced pain and increased exercise capacity without side effects.
However, he also disclosed that he had been administering double the prescribed dose of both peptides.
The nurse advised Norton to return to the prescribed dosage from the following week. The doctor subsequently authorised a replacement vial.
This decision later attracted criticism from the coroner. The clinic had already received information that Norton was taking more than the prescribed amount, yet the replacement was authorised without directly confirming with him that he was using the medication appropriately.
The circumstances surrounding that decision became an important part of the subsequent medical and regulatory investigation.
Fatal Anaphylactic Reaction After Another Peptide Injection
Later on March 28, Norton administered another injection of CJC1295 and Ipamorelin.
His wife, Judy Norton, reported that he felt hot and flushed shortly after the injection before collapsing and becoming unresponsive.
Emergency services were contacted, and CPR was initiated. Paramedics subsequently arrived, found Norton in cardiac arrest and resuscitated him before transporting him to Melbourne’s Alfred Hospital.
The investigation also uncovered evidence of possible allergic symptoms following earlier injections.
Medical evidence identified local redness and swelling followed by whole-body flushing after previous administrations. On the morning of March 28, Norton had additionally experienced whole-body flushing, chest tightness and shortness of breath. These symptoms reportedly improved after he used his Ventolin inhaler.
The later reaction was considerably more serious.
Despite receiving hospital treatment following the cardiac arrest, Norton developed further complications. He died at the Alfred Hospital on March 30, 2025, at 10:17 a.m.
What the Coroner Established About Richard Norton’s Cause of Death
The formal coronial finding provides a more specific explanation than simply describing Norton’s death as a heart attack.
The recorded cause of death was:
1(a) Complications of an out-of-hospital cardiac arrest
1(b) Anaphylaxis
2. Asthma, hypertrophic cardiomyopathy.
The forensic investigation identified evidence consistent with anaphylaxis. The forensic pathologist considered the timing of Norton’s symptoms in relation to the peptide injections and favoured the peptides as a possible cause of the allergic reaction.
An autopsy also identified hypertrophic cardiomyopathy, a condition involving abnormal thickening of the heart muscle that was considered capable of increasing the risk associated with cardiac arrest.
Asthma was also identified as a contributing condition.
Although the specific peptides were not detected through post-mortem toxicology, the coroner accepted the medical evidence concerning the timing of the reaction.
The finding concluded that Norton’s death was triggered by the CJC1295/Ipamorelin injection, which caused anaphylaxis leading to cardiac arrest. It also recorded that Norton had been administering amounts above the dose prescribed by his medical practitioner.
Medical Board Investigation Raises Concerns About Prescribing Decisions
The circumstances surrounding Norton’s treatment also prompted an investigation by the Medical Board of Australia after the Australian Health Practitioner Regulation Agency received a notification raising concerns about the care provided by Dr. Muchnicki.
The investigation included an assessment by clinical professor Alistair Vickery.
Vickery concluded that there was:
“insufficient evidence that CJC1295/Ipamorelin is safe, effective or beneficial for human use.”
His assessment did not, however, amount to a finding that every aspect of Muchnicki’s clinical care had fallen below the required standard.
Factors considered included the doctor’s training and experience, Norton’s informed consent and his previous peptide use without reported adverse effects.
Nevertheless, Vickery criticised the medical documentation, describing the records as:
“sparse, inadequate and perfunctory.”
He also questioned the decision to authorise the replacement vial on March 28 without directly contacting Norton to confirm appropriate use or assess possible misuse and adverse effects.
Doctor apologised and received professional conditions
According to the coronial finding, Muchnicki accepted accountability for his actions and apologised for errors in judgment and lapses in record keeping. He also expressed sorrow over the impact of Norton’s death on Norton and his family.
He subsequently reflected on the circumstances and committed to improving his professional standards.
He engaged an educator to provide one-on-one education concerning clinical record keeping and management. He also indicated that he would no longer prescribe peptides unless robust clinical evidence supported their use.
In July 2026, the Medical Board determined that Muchnicki’s practice “is or may be unsatisfactory” in relation to the issues identified during the investigation.
The board decided that further regulatory action was not warranted concerning the broader clinical care provided to Norton. However, it issued Muchnicki a caution and imposed conditions on his registration, including additional education relating to clinical record keeping and management, followed by an audit.
Why Unapproved Peptides Are Under Growing TGA Scrutiny
Norton’s death occurred amid increasing concerns about the promotion, availability and use of unapproved peptide products in Australia.
CJC1295 and Ipamorelin were not listed on the Australian Register of Therapeutic Goods and had therefore not undergone the TGA’s ordinary assessment for safety, quality and effectiveness as approved therapeutic products.
The TGA also told the Coroners Court that other peptides considered in Norton’s treatment, including BPC157, Thymosin B4 and TB-500, were unapproved therapeutic goods.
However, the term unapproved does not automatically mean a substance cannot be accessed under any circumstances.
Australian regulatory arrangements allow medical practitioners to access certain unapproved therapeutic goods for patients under their care through established pathways when the applicable requirements are met.
The TGA’s guidance confirms that some unapproved peptide products can be accessed through these arrangements where clinically appropriate. However, their safety, quality and effectiveness have not been assessed by the regulator.
TGA and Chief Medical Officer issued a warning in June 2026
In June 2026, the TGA and Australia’s Chief Medical Officer released a joint statement warning about the growing availability, promotion and use of unapproved peptides.
The statement highlighted reports received by the TGA and hospitalisation data identifying serious adverse effects associated with some products.
These included liver damage, severe allergic reactions requiring hospitalisation, inflammation and other health complications.
CJC-1295 was specifically listed among examples of peptide products that may be unapproved when they are not included in the Australian Register of Therapeutic Goods.
The regulator also warned that important information could be unavailable concerning manufacturing standards, sterility, ingredients, dosing and potential side effects.
Some products were reportedly being sold online as powders or injections in poorly labelled or unmarked vials.
September 2026 guidance highlights online peptide promotion
The TGA updated its peptide-specific guidance on September 23, 2026, addressing the increasing promotion of peptide products online and through social media.
These products were being promoted for purposes including weight loss, muscle growth, anti-ageing, recovery and performance enhancement.
The regulator distinguished between approved peptide medicines and unapproved therapeutic goods, warning that unapproved products had not undergone its assessment for safety, quality or effectiveness.
Consequently, there was no assurance that they were safe, effective, correctly labelled, sterile or manufactured to appropriate standards.
The TGA also reported enforcement activity during August 2026. In an operation conducted with NSW Police, it seized more than A$120,000 worth of illicit peptide and anabolic steroid products from two residential properties in New South Wales.
Although these broader enforcement actions were separate from Norton’s case, they demonstrated the regulatory concerns surrounding the supply and promotion of unapproved peptide products.
Coroner Recommends TGA Review of CJC1295 and Ipamorelin
The most significant regulatory development came with Coroner David Ryan’s findings on October 28, 2026.
After considering the medical and regulatory evidence, Ryan recommended that the Therapeutic Goods Administration review the therapeutic benefits and safety risks of CJC1295 and Ipamorelin.
He also recommended that the regulator consider whether additional restrictions should be imposed on their use.
One possibility specifically identified was moving the substances from Schedule 4 towards Schedule 10 under Australia’s Poisons Standard.
Schedule 10 is reserved for substances considered sufficiently dangerous to health to warrant prohibition of supply and use. The coroner noted that a future regulatory approach could potentially provide exceptions for clinical trials or other experimental use.
Ryan said he was not satisfied that CJC1295 and Ipamorelin should remain available for ordinary prescribing given the uncertainties surrounding their therapeutic benefits and safety risks.
Importantly, the recommendation does not itself change the substances’ legal classification. Any scheduling alteration would need to proceed through the appropriate regulatory process.
The Coroners Court’s findings page also explains that when a recommendation is made to a public statutory authority, the authority must respond in writing within three months, stating what action, if any, it intends to take.
Has Australia Banned CJC1295 and Ipamorelin?
Despite the coroner’s recommendation, CJC1295 and Ipamorelin have not automatically been moved to Schedule 10.
As of October 31, 2026, the recommendation remains under regulatory consideration.
Following the coronial finding, the TGA said it continued to warn consumers about unapproved peptides that had not been assessed for safety, quality or effectiveness.
The regulator also confirmed that it was continuing to assess the risks associated with these products and considering whether further regulatory or other measures might be appropriate.
The distinction matters: a recommendation for tighter restrictions is not the same as an enacted scheduling change.
Looking Back at an Actor’s Legacy
Readers following detailed reporting on the deaths of well-known actors can also explore our coverage of Heath Ledger’s death, including the official cause and his career legacy. Read our Heath Ledger death and legacy explainer.
Conclusion: Richard Norton’s Death Raises Wider Questions About Peptide Safety
Richard Norton’s death has brought attention to the potential risks associated with unapproved peptide therapies and the safeguards surrounding their prescription and use.
The Victorian Coroners Court concluded that an injection of CJC1295 and Ipamorelin triggered an anaphylactic reaction that led to cardiac arrest. Norton’s asthma and hypertrophic cardiomyopathy were identified as contributing factors, while the investigation also established that he had been taking more than the prescribed dose.
The case does not establish that every peptide product carries identical risks. Peptides represent a broad category of substances, and some peptide-based medicines are approved for specific medical uses. Their regulatory status, evidence base and risks can differ considerably.
However, Norton’s case has raised important questions about clinical evidence, informed consent, prescribing decisions, dosing, patient monitoring, medical record keeping and the regulation of unapproved therapeutic goods.
With the TGA already warning about unapproved peptide products and the coroner now recommending a review of CJC1295 and Ipamorelin, the future regulatory position remains an important issue for Australian health authorities.
For now, the coronial finding has established the circumstances of Norton’s death, while the question of whether these two peptides should face significantly tighter restrictions remains before the regulator.
Source and Research Disclaimer: This article has been prepared following a review of the sources provided below, including the Victorian Coroners Court finding, reporting by ABC News and official Therapeutic Goods Administration publications. It reflects the information available in those sources as of October 31, 2026. The article does not imply independent verification beyond the material contained in the cited sources. Regulatory recommendations and decisions may change as the relevant Australian authorities review the matter.
Sources
- Victorian Coroners Court: Richard John Norton, Finding into Death Without Inquest (October 28, 2026)
- ABC News: Coroner recommends TGA review peptide restrictions after Australian actor’s death
- Therapeutic Goods Administration: Concerns regarding the public health risks associated with unapproved peptide products
- Therapeutic Goods Administration: Peptide products
- Therapeutic Goods Administration: Warning on the risks of importing unapproved peptide products
Featured Image Credit: Australasian Martial Arts Hall of Fame / CC BY-SA 4.0 / Wikimedia Commons
Leave a Reply